Journal of Clinical Oncology
Articles in this Issue
A randomized phase III trial of dexamethasone mouthwash to prevent chemotherapy-induced oral mucositis in patients with breast cancer.
12017 Background: Oral mucositis is a common adverse event in patients undergoing chemotherapy for breast cancer. A previo...
Knowledge characterization of newly diagnosed breast cancer patients.
e12738 Background: Patient decision making is understudied and seldom focused on those diagnosed with cancer. This NCI-sup...
Concurrent RNA- and DNA-NGS testing for the detection of clinically-relevant fusions in pediatric solid-tumor patients.
10035 Background: Identifying structural rearrangements and gene fusions is critical to providing high quality, precision-...
Hair relaxer use and breast cancer risk by tumor molecular subtypes.
10596 Background: Women of West African ancestry, including US populations, are disproportionately diagnosed with aggressi...
p53 R248Q upregulation of VTCN1 via dual mechanisms as a driver of immune evasion and adaptive resistance to CDK4/6 inhibitors: Rationale for combination immunotherapy in endometrial cancer.
5618 Background: TP53-mutated endometrial cancer (EC) is a heterogeneous disease with variable responses to immunotherapy....
Comparative mortality following intracranial hemorrhage in patients with brain metastases from melanoma vs renal cell carcinoma: A propensity score–matched analysis.
e14027 Background: Melanoma and renal cell carcinoma (RCC) frequently metastasize to the brain and carry high hemorrhagic...
Engineering and evaluating intelligent information retrieval systems for hepatocellular carcinoma clinical question answering.
e16009 Background: Large language models (LLMs) help navigate complex clinical guidelines but often suffer from hallucinat...
Prevalence of high Claudin 18 expression in gallbladder cancer and association with survival: Implications for CLDN18.2-targeted therapy.
e16299 Prevalence of high Claudin 18 expression in gallbladder cancer and association with survival: implications for CLDN18.2-targeted therap...
A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non–small cell lung cancer (NSCLC) (TeLuRide-008).
TPS8668 Background: Immune checkpoint inhibitors (ICIs) reverse tumor-induced immune suppression and promote effective ant...
Beyond local mucosal patterns: Vision transformer–based modeling for diagnosis of gastric tumors on endoscopic imaging.
e15515 Background: Gastric cancer remains a leading cause of cancer-related mortality worldwide, largely due to delayed di...
Olanzapine for weight gain in children undergoing chemotherapy for solid-organ malignancies: An investigator-initiated, open-label, multicenter, phase III randomized controlled trial (SNOWMAN).
10053 Background: Children receiving intensive chemotherapy for solid-organ malignancies frequently experience deteriorati...
Total neoadjuvant chemotherapy with FLOT for resectable gastric and gastroesophageal junction adenocarcinoma: Real-world outcomes from a Chilean oncology institution.
e15720 Background: Perioperative FLOT improves survival and pathological complete response (pCR) in resectable gastric can...
Comparative benchmarking of U.S. oncology populations and survival using a multi-health system EHR data.
e23401 Background: Real-world oncology research relies on electronic health record (EHR) data that are representative of t...
iPREDICT: Phase II study of CD8 PET in patients with immunoresponsive solid tumors—Imaging characteristics and correlation with RECIST response.
3069 Background: CD8 T cells mediate antitumor effects of immune checkpoint blockade (ICB); their histologically-determine...
Real-world retrospective analysis of outcomes, treatment duration, dose intensity, and safety of enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.
e16580 Background: Enfortumab vedotin (EV) in combination with pembrolizumab (P) has been FDA-approved for patients with l...
Targeting ALKBH5 with mefloquine as a therapeutic strategy to enhance antitumor immunity in osteosarcoma.
e14596 Background: Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents, with a second...
Analyzing dual threat shifts in gastric carcinoma and sepsis mortality in the United States from 1999-2020: Insights from CDC database.
e16067 Background: Gastric carcinoma remains a significant cause of cancer mortality in the United States. Although overal...
Phase 1/2 trial of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment–mediated pathways of resistance from correlative data.
3141 Background: Herein we present novel correlative data from baseline and on-treatment tumor and blood sampling with ass...
A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.
4037 Background: CLDN18.2 is a highly selective tumor-associated antigen overexpressed in gastrointestinal malignancies, a...
Radiology-NLP–derived real-world progression endpointing and clinicogenomic correlates after 177Lu-DOTATATE PRRT in pancreatic neuroendocrine tumors in MSK-CHORD 2024.
e16329 Background: Predictive biomarkers for peptide receptor radionuclide therapy (PRRT) in pancreatic neuroendocrine tum...
Endometrial cancer mortality and persistent disparities in the United States, 1999–2023.
e17646 Background: Endometrial cancer (EC) is the most common gynecologic malignancy in high-income countries, with a risi...
Testosterone suppression, safety, and adherence with relugolix in patients with metastatic prostate cancer: 6-month subgroup analysis of the OPTYX study.
e17057 Background: Relugolix is an oral androgen deprivation therapy used for the treatment of advanced prostate cancer (P...
Prognostic stratification using baseline objective clinical information in patients with stage IV lung cancer receiving best supportive care alone as initial treatment: A multicenter retrospective study (WJOG20824L).
12054 Background: Despite expanded systemic therapy for lung cancer, best supportive care (BSC) alone remains the initial...
CLD-401: A next-generation systemic gene therapy for tumor-localized expression of IL-15 superagonist.
e14517 Background: RedTail is a next-generation gene therapy platform engineered for systemic delivery and highly selectiv...
Therapeutic strategies and reduced drug spending as a signal of early impact of the Enhancing Oncology Model.
1578 Background: Building on lessons learned from the predecessor Oncology Care Model, the Centers for Medicare & Medi...